1. The document discusses the ideal anticoagulant therapy for high risk PCI and ACS, stating that bivalirudin is the ideal option. 2. It discloses conflicts of interest for the author Dr. Montalescot related to research funding from various pharmaceutical companies. 3. The slides that follow debate the claims that bivalirudin is superior or ideal, pointing to studies that show it is not more effective or safer than unfractionated heparin at recommended doses, and that alternatives like radial access and newer antiplatelets may be better options.